Literature DB >> 10097823

Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura.

M Furlan1, B Lämmle.   

Abstract

Excessive intravascular platelet agglutination in patients with thrombotic thrombocytopenic purpura (TTP) appears to be associated with excessive release from endothelial cells of unusually large von Willebrand factor (vWF) multimers and/or impaired degradation of these multimers by a 'depolymerase' cleaving vWF to smaller, non-agglutinating molecular forms. We studied the activity of a recently described vWF-cleaving protease in four patients, including two brothers, with chronic relapsing TTP. All four patients had lacking or strongly reduced vWF-cleaving protease activity. In another patient with chronic relapsing TTP, the protease deficiency was due to the presence in the patient plasma of an inhibitor that was found to be an IgG. We conclude that constitutional as well as acquired deficiency of vWF-cleaving protease may predispose to clinical manifestation of TTP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10097823     DOI: 10.1016/s0950-3536(98)80064-4

Source DB:  PubMed          Journal:  Baillieres Clin Haematol        ISSN: 0950-3536


  16 in total

1.  The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.

Authors:  Jihui Ai; Paula Smith; Shuwei Wang; Ping Zhang; X Long Zheng
Journal:  J Biol Chem       Date:  2005-06-23       Impact factor: 5.157

Review 2.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

3.  Unconjugated bilirubin inhibits proteolytic cleavage of von Willebrand factor by ADAMTS13 protease.

Authors:  R-N Lu; S Yang; H M Wu; X L Zheng
Journal:  J Thromb Haemost       Date:  2015-04-23       Impact factor: 5.824

4.  Current status in diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura.

Authors:  Hayley A Hanby; X Long Zheng
Journal:  Hereditary Genet       Date:  2014

Review 5.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

6.  Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens.

Authors:  John-Paul Westwood; Mari Thomas; Ferras Alwan; Vickie McDonald; Sylvia Benjamin; William A Lester; Gillian C Lowe; Tina Dutt; Quentin A Hill; Marie Scully
Journal:  Blood Adv       Date:  2017-06-26

7.  Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes.

Authors:  Masami Niiya; Masayuki Endo; Dezhi Shang; Philip W Zoltick; Nidal E Muvarak; Wenjing Cao; Sheng-Yu Jin; Christopher G Skipwith; David G Motto; Alan W Flake; X Long Zheng
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

8.  Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.

Authors:  Pablo Laje; Dezhi Shang; Wenjing Cao; Masami Niiya; Masayuki Endo; Antoneta Radu; Nicole DeRogatis; Friedrich Scheiflinger; Philip W Zoltick; Alan W Flake; X Long Zheng
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

Review 9.  Pathogenesis of thrombotic microangiopathies.

Authors:  X Long Zheng; J Evan Sadler
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

10.  Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13.

Authors:  Wenjing Cao; Sriram Krishnaswamy; Rodney M Camire; Peter J Lenting; X Long Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.